Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study

Lucien Noens, Marie Anne Van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald, Sabina De Geest, Tara Albrecht, Ivo L Abraham

Research output: Contribution to journalArticle

398 Citations (Scopus)

Abstract

Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.

Original languageEnglish (US)
Pages (from-to)5401-5411
Number of pages11
JournalBlood
Volume113
Issue number22
DOIs
StatePublished - 2009

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Outcome Assessment (Health Care)
Therapeutics
Patient Compliance
Imatinib Mesylate
Belgium
Physicians

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia : The ADAGIO study. / Noens, Lucien; Van Lierde, Marie Anne; De Bock, Robrecht; Verhoef, Gregor; Zachée, Pierre; Berneman, Zwi; Martiat, Philippe; Mineur, Philippe; Van Eygen, Koen; MacDonald, Karen; De Geest, Sabina; Albrecht, Tara; Abraham, Ivo L.

In: Blood, Vol. 113, No. 22, 2009, p. 5401-5411.

Research output: Contribution to journalArticle

Noens, L, Van Lierde, MA, De Bock, R, Verhoef, G, Zachée, P, Berneman, Z, Martiat, P, Mineur, P, Van Eygen, K, MacDonald, K, De Geest, S, Albrecht, T & Abraham, IL 2009, 'Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study', Blood, vol. 113, no. 22, pp. 5401-5411. https://doi.org/10.1182/blood-2008-12-196543
Noens, Lucien ; Van Lierde, Marie Anne ; De Bock, Robrecht ; Verhoef, Gregor ; Zachée, Pierre ; Berneman, Zwi ; Martiat, Philippe ; Mineur, Philippe ; Van Eygen, Koen ; MacDonald, Karen ; De Geest, Sabina ; Albrecht, Tara ; Abraham, Ivo L. / Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia : The ADAGIO study. In: Blood. 2009 ; Vol. 113, No. 22. pp. 5401-5411.
@article{b88bc8dd0fdd4ff684cec9dafa7431b5,
title = "Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study",
abstract = "Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2{\%} of patients were perfectly adherent with 100{\%} of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2{\%}, standard deviation [SD] = 23.8) than did those with optimal response (7.3{\%}, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.",
author = "Lucien Noens and {Van Lierde}, {Marie Anne} and {De Bock}, Robrecht and Gregor Verhoef and Pierre Zach{\'e}e and Zwi Berneman and Philippe Martiat and Philippe Mineur and {Van Eygen}, Koen and Karen MacDonald and {De Geest}, Sabina and Tara Albrecht and Abraham, {Ivo L}",
year = "2009",
doi = "10.1182/blood-2008-12-196543",
language = "English (US)",
volume = "113",
pages = "5401--5411",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia

T2 - The ADAGIO study

AU - Noens, Lucien

AU - Van Lierde, Marie Anne

AU - De Bock, Robrecht

AU - Verhoef, Gregor

AU - Zachée, Pierre

AU - Berneman, Zwi

AU - Martiat, Philippe

AU - Mineur, Philippe

AU - Van Eygen, Koen

AU - MacDonald, Karen

AU - De Geest, Sabina

AU - Albrecht, Tara

AU - Abraham, Ivo L

PY - 2009

Y1 - 2009

N2 - Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.

AB - Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.

UR - http://www.scopus.com/inward/record.url?scp=67049087117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049087117&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-12-196543

DO - 10.1182/blood-2008-12-196543

M3 - Article

C2 - 19349618

AN - SCOPUS:67049087117

VL - 113

SP - 5401

EP - 5411

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -